Zacks: Brokerages Anticipate Arsanis Inc (ASNS) to Announce -$0.49 EPS

Equities research analysts predict that Arsanis Inc (NASDAQ:ASNS) will announce earnings per share (EPS) of ($0.49) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Arsanis’ earnings. The firm is expected to report its next earnings report on Monday, November 12th.

On average, analysts expect that Arsanis will report full year earnings of ($3.12) per share for the current year, with EPS estimates ranging from ($3.46) to ($2.46). For the next year, analysts anticipate that the company will report earnings of ($2.54) per share, with EPS estimates ranging from ($3.56) to ($1.51). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Arsanis.

Arsanis (NASDAQ:ASNS) last released its quarterly earnings data on Monday, August 13th. The company reported ($0.85) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by ($0.03).

ASNS has been the topic of several recent analyst reports. Zacks Investment Research upgraded Arsanis from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a report on Tuesday, July 10th. Piper Jaffray Companies cut their price objective on Arsanis to $2.50 and set a “neutral” rating on the stock in a report on Monday, August 13th. Citigroup cut Arsanis from a “buy” rating to a “neutral” rating in a report on Monday, July 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $26.00 target price on shares of Arsanis in a research report on Thursday, June 28th. Finally, Cowen lowered Arsanis from an “outperform” rating to a “market perform” rating in a research report on Monday, July 2nd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Arsanis presently has a consensus rating of “Hold” and an average price target of $14.88.

Institutional investors have recently made changes to their positions in the stock. New York State Common Retirement Fund acquired a new stake in Arsanis in the 1st quarter valued at approximately $114,000. California State Teachers Retirement System acquired a new stake in Arsanis in the 1st quarter valued at approximately $162,000. Schwab Charles Investment Management Inc. acquired a new stake in Arsanis in the 1st quarter valued at approximately $200,000. Millennium Management LLC acquired a new stake in Arsanis in the 4th quarter valued at approximately $299,000. Finally, Northern Trust Corp acquired a new stake in Arsanis in the 1st quarter valued at approximately $735,000. 68.70% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:ASNS traded down $0.08 during trading on Thursday, hitting $1.81. 50,700 shares of the company’s stock traded hands, compared to its average volume of 86,593. Arsanis has a 52 week low of $1.70 and a 52 week high of $28.69. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.54 and a quick ratio of 5.54. The stock has a market capitalization of $26.63 million and a PE ratio of -0.11.

About Arsanis

Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.

Read More: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Arsanis (ASNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arsanis (NASDAQ:ASNS)

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply